Management of Mixed Dyslipidemia

Risk Assessment and Treatment Rationale

The European Society of Cardiology recommends calculating a patient's 10-year cardiovascular risk to determine treatment intensity, with a goal of <5% risk for initiating lipid-lowering therapy 1, 2
Patients with elevated LDL-C (>115 mg/dL) and moderate hypertriglyceridemia (200-499 mg/dL) are at increased cardiovascular risk, and lipid-lowering drug therapy should be considered even after lifestyle modifications 1, 2
The American Heart Association suggests that a lipid profile with elevated total cholesterol (>190 mg/dL), LDL-C (>115 mg/dL), and non-HDL-C (>145 mg/dL) indicates increased cardiovascular risk 4, 5

The European Society of Cardiology recommends initiating moderate-intensity statin therapy (atorvastatin 10-20 mg or rosuvastatin 5-10 mg daily) as first-line treatment for mixed dyslipidemia, providing 30-50% LDL-C reduction and 10-30% triglyceride reduction 6, 3
Statin therapy addresses both elevated LDL-C and moderately elevated triglycerides simultaneously, making it the optimal initial pharmacologic choice 3

The American Heart Association recommends a 5-10% body weight reduction, which produces a 20% triglyceride decrease, and engaging in ≥150 minutes/week of moderate-intensity aerobic activity, reducing triglycerides by ~11% 3
The Academy of Nutrition and Dietetics suggests restricting added sugars to <6% of total daily calories, limiting total dietary fat to 30-35% of total calories, and restricting saturated fats to <7% of total energy intake 3

The European Society of Cardiology recommends reassessing fasting lipid panel in 6-12 weeks after implementing lifestyle modifications and statin therapy, with target goals of LDL-C <115 mg/dL, triglycerides <150 mg/dL, and non-HDL-C <145 mg/dL 1, 2, 4, 5, 6

The American Diabetes Association recommends considering add-on therapy with icosapent ethyl 2-4g daily if triglycerides remain >200 mg/dL after 3 months of optimized statin therapy and lifestyle modifications, providing a 25% reduction in major adverse cardiovascular events 6, 3
The European Society of Cardiology suggests considering fenofibrate 54-160 mg daily if triglycerides remain persistently >200 mg/dL, providing 30-50% triglyceride reduction 3